GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38869449.
- Also identified by DOI 10.1158/1078-0432.CCR-24-0486.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication. See related article by Fischer-Riepe et al., p. 3564.
Medical subject headings
- Receptors, Chimeric Antigen
- Immunotherapy, Adoptive
- T-Lymphocytes
- Neoplasms